Modality
Nanobody
MOA
IL-17i
Target
PD-L1
Pathway
Incretin
Urothelial CaADPKDNSCLC
Development Pipeline
Preclinical
~Sep 2015
→ ~Dec 2016
Phase 1
Mar 2017
→ Jan 2029
Phase 1Current
NCT06163185
1,533 pts·ADPKD
2017-03→2027-01·Completed
NCT03323542
124 pts·Urothelial Ca
2024-11→2029-01·Active
1,657 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-02-171mo agoAdCom· NSCLC
2027-01-139mo awayPh2 Data· ADPKD
2029-01-122.8y awayPh2 Data· Urothelial Ca
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P1/2
Complet…
P1/2
Active
Catalysts
AdCom
2026-02-17 · 1mo ago
NSCLC
Ph2 Data
2027-01-13 · 9mo away
ADPKD
Ph2 Data
2029-01-12 · 2.8y away
Urothelial Ca
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06163185 | Phase 1/2 | ADPKD | Completed | 1533 | NT-proBNP |
| NCT03323542 | Phase 1/2 | Urothelial Ca | Active | 124 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| Polatuximab | Nuvalent | Approved | PD-L1 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 |